These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 19893491)

  • 1. CYLD negatively regulates cell-cycle progression by inactivating HDAC6 and increasing the levels of acetylated tubulin.
    Wickström SA; Masoumi KC; Khochbin S; Fässler R; Massoumi R
    EMBO J; 2010 Jan; 29(1):131-44. PubMed ID: 19893491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Downregulation of cylindromatosis gene, CYLD, confers a growth advantage on malignant melanoma cells while negatively regulating their migration activity.
    Ishikawa Y; Tsunoda K; Shibazaki M; Takahashi K; Akasaka T; Masuda T; Maesawa C
    Int J Oncol; 2012 Jul; 41(1):53-60. PubMed ID: 22469839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CYLD mediates ciliogenesis in multiple organs by deubiquitinating Cep70 and inactivating HDAC6.
    Yang Y; Ran J; Liu M; Li D; Li Y; Shi X; Meng D; Pan J; Ou G; Aneja R; Sun SC; Zhou J
    Cell Res; 2014 Nov; 24(11):1342-53. PubMed ID: 25342559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of the tumor suppressor CYLD enhances Wnt/beta-catenin signaling through K63-linked ubiquitination of Dvl.
    Tauriello DV; Haegebarth A; Kuper I; Edelmann MJ; Henraat M; Canninga-van Dijk MR; Kessler BM; Clevers H; Maurice MM
    Mol Cell; 2010 Mar; 37(5):607-19. PubMed ID: 20227366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyld inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-kappaB signaling.
    Massoumi R; Chmielarska K; Hennecke K; Pfeifer A; Fässler R
    Cell; 2006 May; 125(4):665-77. PubMed ID: 16713561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CENPV Is a CYLD-Interacting Molecule Regulating Ciliary Acetylated α-Tubulin.
    Chiticariu E; Regamey A; Huber M; Hohl D
    J Invest Dermatol; 2020 Jan; 140(1):66-74.e4. PubMed ID: 31260673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The tumor suppressor CYLD regulates microtubule dynamics and plays a role in cell migration.
    Gao J; Huo L; Sun X; Liu M; Li D; Dong JT; Zhou J
    J Biol Chem; 2008 Apr; 283(14):8802-9. PubMed ID: 18222923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Five new CYLD mutations in skin appendage tumors and evidence that aspartic acid 681 in CYLD is essential for deubiquitinase activity.
    Almeida S; Maillard C; Itin P; Hohl D; Huber M
    J Invest Dermatol; 2008 Mar; 128(3):587-93. PubMed ID: 17851586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone deacetylase 6 (HDAC6) is an independent deacetylase for alpha-tubulin.
    Zhao Z; Xu H; Gong W
    Protein Pept Lett; 2010 May; 17(5):555-8. PubMed ID: 19961433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CYLD regulates keratinocyte differentiation and skin cancer progression in humans.
    Alameda JP; Fernández-Aceñero MJ; Moreno-Maldonado R; Navarro M; Quintana R; Page A; Ramírez A; Bravo A; Casanova ML
    Cell Death Dis; 2011 Sep; 2(9):e208. PubMed ID: 21900959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation.
    Haggarty SJ; Koeller KM; Wong JC; Grozinger CM; Schreiber SL
    Proc Natl Acad Sci U S A; 2003 Apr; 100(8):4389-94. PubMed ID: 12677000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CYLD Inhibits the Development of Skin Squamous Cell Tumors in Immunocompetent Mice.
    Alameda JP; García-García VA; López S; Hernando A; Page A; Navarro M; Moreno-Maldonado R; Paramio JM; Ramírez Á; García-Fernández RA; Casanova ML
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34201751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HDAC6 is a microtubule-associated deacetylase.
    Hubbert C; Guardiola A; Shao R; Kawaguchi Y; Ito A; Nixon A; Yoshida M; Wang XF; Yao TP
    Nature; 2002 May; 417(6887):455-8. PubMed ID: 12024216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of histone deacetylase 6 (HDAC6) nuclear import and tubulin deacetylase activity through acetylation.
    Liu Y; Peng L; Seto E; Huang S; Qiu Y
    J Biol Chem; 2012 Aug; 287(34):29168-74. PubMed ID: 22778253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GLI1-dependent transcriptional repression of CYLD in basal cell carcinoma.
    Kuphal S; Shaw-Hallgren G; Eberl M; Karrer S; Aberger F; Bosserhoff AK; Massoumi R
    Oncogene; 2011 Nov; 30(44):4523-30. PubMed ID: 21577203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transition from cylindroma to spiradenoma in CYLD-defective tumours is associated with reduced DKK2 expression.
    Rajan N; Burn J; Langtry J; Sieber-Blum M; Lord CJ; Ashworth A
    J Pathol; 2011 Jul; 224(3):309-21. PubMed ID: 21598248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of CYLD might be associated with development of salivary gland tumors.
    Fukuda M; Hiroi M; Suzuki S; Ohmori Y; Sakashita H
    Oncol Rep; 2008 Jun; 19(6):1421-7. PubMed ID: 18497946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional interplay between cylindromatosis and histone deacetylase 6 in ciliary homeostasis revealed by phenotypic analysis of double knockout mice.
    Ran J; Yu F; Qin J; Zhang Y; Yang Y; Li D; Zhou J; Liu M
    Oncotarget; 2016 May; 7(19):27527-37. PubMed ID: 27028867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MeCP2 deficiency is associated with reduced levels of tubulin acetylation and can be restored using HDAC6 inhibitors.
    Gold WA; Lacina TA; Cantrill LC; Christodoulou J
    J Mol Med (Berl); 2015 Jan; 93(1):63-72. PubMed ID: 25209898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of CYLD, NF-kappaB and NF-kappaB-related factors in salivary gland tumors.
    Fukuda M; Fukuda F; Horiuchi Y; Oku Y; Suzuki S; Kusama K; Sakashita H
    In Vivo; 2006; 20(4):467-72. PubMed ID: 16900776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.